Non-HDL cholesterol should not generally replace LDL cholesterol in the management of hyperlipidaemia
Recently non-HDL cholesterol has been recommended to replace LDL cholesterol in the clinical management of dyslipidaemia routinely in general medical practice. The authors claim this is misguided.
Related stories
- Ketogenic Diet and Lipids
- Low Carbohydrate diets, Weight management, Type 2 diabetes and Dyslipidaemia
- Enablers and barriers to treatment adherence in heterozygous familial hypercholesterolaemia: a qualitative evidence synthesis
- Diagnosis, management and prognosis of familial hypercholesterolaemia in a UK tertiary cardiac centre
- Volanesorsen and Triglyceride Levels in Familial Chylomicronemia Syndrome
- Does diet quality or nutrient quantity contribute more to health?
- Pharmacological lipid-modification therapies for prevention of ischaemic heart disease: current and future options
- Current management of children and young people with heterozygous familial hypercholesterolaemia - HEART UK statement of care
- Identifying FH Using a Blood Donor Screening Program With More Than 1 Million Volunteer Donors
- Higher circulating and tissue levels of Linoleic Acid associated with lower risk of major cardiovascular events
- Substituting red meat with high-quality plant protein sources results in favourable changes in blood lipids and lipoproteins
- Using metabolic profiling and gene expression analyses to explore molecular effects of replacing saturated fat with polyunsaturated fat—a randomized controlled dietary intervention study
- The Timing of Cardiovascular Health Decline and Its Association With Subclinical Atherosclerosis in Adulthood
- Is diet management helpful in familial hypercholesterolemia? Lynne Garton our Dietetic Adviser, explores.
- Statins may have a role in treating serious mental illness
- Increased intensity plus adherence maximises statin benefits
- Serum Cholesterol and Incident Alzheimer's Disease: Findings from the Adult Changes in Thought Study
- Higher intakes of fibre and wholegrains associated with lower rates of non-communicable diseases, including Cardiovascular Disease and Coronary Heart Disease.
- Risk of Ischemic Stroke and Total Cerebrovascular Disease in Familial Hypercholesterolemia May Not Be Higher
- CVD Prevention Return on Investment Tool
- Cholesterol Management Clinical Practice Guidelines in US
- REDUCE-IT: 25% Reduction in MACE With High-Dose EPA
- Raised Lp(a) Slashed in CV Patients on Novel Antisense Agent
- Integration of child–parent screening and cascade testing for familial hypercholesterolaemia
- Optimising treatment of hyperlipidaemia: Quantitative evaluation of UK, USA and European guidelines taking account of both LDL cholesterol levels and cardiovascular disease risk
- Walnut Consumption Controlled Trial
- Erectile Dysfunction Linked to Future CVD Events
- Ezetimibe - Likely to Be Beneficial For All
- Adverse effects of statin therapy: perception vs. the evidence
- Levels of lipoprotein(a) [Lp(a)] need to be reduced by substantially more than has been achieved in recent trials
- Impact of Healthy Lifestyle Factors on Life Expectancies in the US Population
- How much does plasma lipoprotein(a) need to be lowered to produce a clinically meaningful reduction in the risk of coronary heart disease?
- The effects of Vitamin D supplementation on statin adherence
- Effect of combined treatment with bisphosphonate and vitamin D on atherosclerosis in patients with systemic lupus erythematosus: a propensity score-based analysis
- Efficacy and Safety of Further Lowering of Low-Density Lipoprotein Cholesterol in Patients Starting With Very Low Levels
- Diabetes UK Launches new evidence based guidelines for the prevention and management of diabetes
- Effects of walnut consumption on blood lipids and other cardiovascular risk factors: an updated meta-analysis and systematic review of controlled trials
- Portfolio Dietary Pattern and Cardiovascular Disease: A Systematic Review and Meta-analysis of Controlled Trials
- Omega-3 fatty acids for the primary and secondary prevention of cardiovascular disease
- The complex molecular genetics of familial hypercholesterolaemia
- Parents’ views of genetic testing and treatment of familial hypercholesterolemia in children: a qualitative study
- Universal screening at age 1-2 years as an adjunct to cascade testing for familial hypercholesterolaemia in the UK: A cost-utility analysis.
- Marriage Tied to Lower Risk of Fatal Heart Attacks and Strokes
- How do the experiences and beliefs of adults and children with heterozygous familial hypercholesterolaemia influence their adherence to treatment? A systematic review of qualitative evidence protocol.
- Special Issue Section: Improving the Global Care of Familial Hypercholesterolaemia
- Familial hypercholesterolaemia patient support groups and advocacy: A multinational perspective
- Special Issue Section: Improving the Global Care of Familial Hypercholesterolaemia
- SHARP Annual Scientific Meeting 2018: Save the Date
- Issues & Answers in Cardiovascular Disease, 16-17 November 2018, EMCC Nottingham UK
- HEART UK responds to debate on the true benefits and risks of statins
- HEART UK statement on the management of homozygous familial hypercholesterolaemia in the United Kingdom
- HEART UK study finds high street restaurants serve meals with four times recommended saturated fat
- HEART UK responds to study that says good cholesterol may not always protect you from heart disease
To help support our work please donate
Donate now